JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwartz, D. D.
Right arrow Articles by Malik, K. U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwartz, D. D.
Right arrow Articles by Malik, K. U.

Renal periarterial nerve stimulation-induced vasoconstriction at low frequencies is primarily due to release of a purinergic transmitter in the rat

DD Schwartz and KU Malik

Department of Pharmacology, University of Tennessee, Memphis.

In the isolated rat kidney, the vasoconstrictor response elicited by periarterial nerve stimulation at low frequencies (2 Hz) is resistant to alpha adrenergic receptor blockade. It has been proposed that in some blood vessels ATP is coreleased with norepinephrine during nerve stimulation to activate P2-purinergic receptors and is responsible for the component of the vasoconstrictor response that is resistant to alpha adrenergic receptor blockade. To assess the contribution of a purinergic transmitter in the vasoconstriction elicited by periarterial nerve stimulation in the isolated Tyrodes-perfused rat kidney, fractional overflow of [3H]norepinephrine and vasoconstrictor responses to renal nerve stimulation were examined after alpha adrenergic receptor blockade and/or P2-purinergic receptor desensitization. The alpha-1 adrenergic receptor antagonists prazosin (0.1-1.0 microM) and corynanthine (0.1-1.0 microM) and the nonselective alpha adrenergic receptor antagonist phentolamine (0.1-1.0 microM) did not significantly reduce vasoconstrictor responses elicited by low frequency (0.5-4 Hz) but attenuated the responses to high-frequency (6-10 Hz) periarterial nerve stimulation. At low-frequency renal nerve stimulation, selective P2-purinergic receptor desensitization abolished the vasoconstriction at 0.5 Hz and dramatically attenuated the responses up to 4 Hz. In the presence of prazosin, the component of the vasoconstrictor response that was resistant to alpha adrenergic receptor blockade at all frequencies of renal nerve stimulation was abolished after treatment with alpha, beta-methylene ATP. On the other hand, in the isolated perfused rabbit kidney, prazosin (1.0 microM) alone reduced dramatically the vasoconstrictor responses to periarterial nerve stimulation over the same frequencies used in the rat.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 250, Issue 3, pp. 764-771, 09/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Physiol. Rev.Home page
G. Burnstock
Physiology and Pathophysiology of Purinergic Neurotransmission
Physiol Rev, April 1, 2007; 87(2): 659 - 797.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X. Zhao, E. W. Inscho, M. Bondlela, J. R. Falck, and J. D. Imig
The CYP450 hydroxylase pathway contributes to P2X receptor-mediated afferent arteriolar vasoconstriction
Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H2089 - H2096.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
E. W. Inscho
P2 receptors in regulation of renal microvascular function
Am J Physiol Renal Physiol, June 1, 2001; 280(6): F927 - F944.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
L. van der Weyden, D. J. Adams, and B. J. Morris
Capacity for Purinergic Control of Renin Promoter via P2Y11 Receptor and cAMP Pathways
Hypertension, December 1, 2000; 36(6): 1093 - 1098.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. Salomonsson, K. Brannstrom, and W. J. Arendshorst
alpha 1-Adrenoceptor subtypes in rat renal resistance vessels: in vivo and in vitro studies
Am J Physiol Renal Physiol, January 1, 2000; 278(1): F138 - F147.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
H. M. Stauss, J.-U. Stegmann, P. B. Persson, and H.-J. Habler
Frequency response characteristics of sympathetic transmission to skin vascular smooth muscles in rats
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 1999; 277(2): R591 - R600.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
V. OBERHAUSER, O. VONEND, and L. C. RUMP
Neuropeptide Y and ATP Interact to Control Renovascular Resistance in the Rat
J. Am. Soc. Nephrol., June 1, 1999; 10(6): 1179 - 1185.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Renal Physiol.Home page
E. W. Inscho, A. K. Cook, V. Mui, and J. Miller
Direct assessment of renal microvascular responses to P2-purinoceptor agonists
Am J Physiol Renal Physiol, April 1, 1998; 274(4): F718 - F727.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Bohmann, L. C. Rump, U. Schaible, and I. von Kugelgen
{alpha}-Adrenoceptor Modulation of Norepinephrine and ATP Release in Isolated Kidneys of Spontaneously Hypertensive Rats
Hypertension, June 1, 1995; 25(6): 1224 - 1231.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Renal Physiol.Home page
E. W. Inscho and A. K. Cook
P2 receptor-mediated afferent arteriolar vasoconstriction during calcium blockade
Am J Physiol Renal Physiol, February 1, 2002; 282(2): F245 - F255.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1989 by the American Society for Pharmacology and Experimental Therapeutics.